NASDAQ:BLRX BioLineRx (BLRX) Stock Forecast, Price & News $2.07 +0.09 (+4.55%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.99▼$2.1250-Day Range$1.23▼$2.4552-Week Range$0.55▼$2.53Volume458,008 shsAverage Volume2.62 million shsMarket Capitalization$127.37 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLineRx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside914.5% Upside$21.00 Price TargetShort InterestHealthy3.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector615th out of 965 stocksPharmaceutical Preparations Industry282nd out of 456 stocks 3.5 Analyst's Opinion Consensus RatingBioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, BioLineRx has a forecasted upside of 914.5% from its current price of $2.07.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.90% of the outstanding shares of BioLineRx have been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently increased by 2.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLRX. Previous Next 2.8 News and Social Media Coverage News SentimentBioLineRx has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioLineRx this week, compared to 1 article on an average week.Search Interest54 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows14 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 2.01% of the stock of BioLineRx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($0.83) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLineRx (NASDAQ:BLRX) StockBioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.Read More BLRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLRX Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comBioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic CancerSeptember 18, 2023 | msn.comAssessing BioLineRx As A Buy After Drug ApprovalSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 18, 2023 | americanbankingnews.comZacks Small Cap Research Analysts Reduce Earnings Estimates for BioLineRx Ltd. (NASDAQ:BLRX)September 17, 2023 | americanbankingnews.comBioLineRx (NASDAQ:BLRX) Price Target Increased to $21.00 by Analysts at HC WainwrightSeptember 16, 2023 | americanbankingnews.comBioLineRx Ltd. (NASDAQ:BLRX) Expected to Earn FY2025 Earnings of ($0.01) Per ShareSeptember 14, 2023 | finance.yahoo.comBLRX: …Go!September 13, 2023 | bizjournals.comWaltham-headquartered BioLineRx gets FDA approval for cancer drugSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 12, 2023 | bizjournals.comPublicly traded biotech firm BioLineRx gets FDA approval for cancer drug with help from Washington UniversitySeptember 11, 2023 | marketwatch.comBioLineRx Shares Climb 22% After FDA Approves Aphexda With FilgrastimSeptember 11, 2023 | proactiveinvestors.comBioLineRx rallies on FDA approval of Aphexda with FilgrastimSeptember 11, 2023 | markets.businessinsider.comBioLineRx: FDA Approves APHEXDA Plus Filgrastim To Mobilize Hematopoietic Stem Cells; Stock UpSeptember 11, 2023 | finance.yahoo.comBioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaSeptember 5, 2023 | finance.yahoo.comBLRX: On Your Marks, Get Set…August 31, 2023 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Q2 2023 Earnings Call TranscriptAugust 30, 2023 | finanznachrichten.deBioLineRx Ltd: BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesAugust 30, 2023 | seekingalpha.comBioLineRx GAAP EPS of -$0.02August 30, 2023 | markets.businessinsider.comBioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. WainwrightAugust 30, 2023 | finance.yahoo.comBioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesAugust 22, 2023 | investing.comBioLineRx (BLRX) Earnings Dates & ReportsAugust 22, 2023 | finance.yahoo.comBioLineRx to Report Second Quarter 2023 Results on August 30, 2023July 17, 2023 | finance.yahoo.comBioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate MotixafortideJune 7, 2023 | finance.yahoo.comBLRX: First Quarter ResultsMay 24, 2023 | finance.yahoo.comBioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesMay 23, 2023 | seekingalpha.combiolinerx Q1 2023 Earnings PreviewMay 17, 2023 | finance.yahoo.comBioLineRx to Report First Quarter 2023 Results on May 24, 2023See More Headlines Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BLRX Company Calendar Last Earnings8/30/2023Today9/24/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLRX CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees49Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+914.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.97% Return on Assets-60.62% Debt Debt-to-Equity Ratio0.40 Current Ratio2.79 Quick Ratio2.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book2.49Miscellaneous Outstanding Shares61,530,000Free Float60,854,000Market Cap$127.37 million OptionableNot Optionable Beta1.80 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Philip A. Serlin CPA (Age 63)M.B.A., CPA, MBA, Chief Exec. Officer Comp: $635kMs. Mali Zeevi CPA (Age 47)CPA, Chief Financial Officer Comp: $380kDr. Ella Sorani (Age 55)Chief Devel. Officer Comp: $457kMs. Holly W. May M.B.A. (Age 61)Pres of BioLineRx USA Comp: $328kMr. John LaceyHead of Corp. Communications & Investor RelationsMr. Adam Janoff Esq.Gen. Counsel & Head of ComplianceMs. Tsipi Keren-Lehrer B.Sc.L.L.B., Head of BD & Strategic AdvisorDr. Tami Rachmilewitz M.D. (Age 52)Chief Medical Officer Mr. Raziel FriedTreasurer & Budgetary Control DirectorMore ExecutivesKey CompetitorsTrevi TherapeuticsNASDAQ:TRVIDesign TherapeuticsNASDAQ:DSGNXBiotechNASDAQ:XBITKaryopharm TherapeuticsNASDAQ:KPTIAnnexonNASDAQ:ANNXView All CompetitorsInstitutional OwnershipOsaic Holdings Inc.Sold 11,052 shares on 8/21/2023Ownership: 0.032%Citadel Advisors LLCBought 100 shares on 8/15/2023Ownership: 0.000%Renaissance Technologies LLCSold 7,379 shares on 8/11/2023Ownership: 0.160%Osaic Holdings Inc.Sold 11,052 shares on 8/10/2023Ownership: 0.032%Envestnet Asset Management Inc.Sold 30,491 shares on 8/4/2023Ownership: 0.111%View All Institutional Transactions BLRX Stock - Frequently Asked Questions Should I buy or sell BioLineRx stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares. View BLRX analyst ratings or view top-rated stocks. What is BioLineRx's stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 914.5% from the stock's current price. View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts. How have BLRX shares performed in 2023? BioLineRx's stock was trading at $0.59 at the beginning of 2023. Since then, BLRX stock has increased by 250.8% and is now trading at $2.07. View the best growth stocks for 2023 here. When is BioLineRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our BLRX earnings forecast. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) released its earnings results on Wednesday, August, 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.14. During the same quarter in the prior year, the business earned ($0.16) earnings per share. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE). What is BioLineRx's stock symbol? BioLineRx trades on the NASDAQ under the ticker symbol "BLRX." Who are BioLineRx's major shareholders? BioLineRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include LPL Financial LLC (0.20%), Renaissance Technologies LLC (0.16%), Envestnet Asset Management Inc. (0.11%), PVG Asset Management Corp (0.10%), Osaic Holdings Inc. (0.03%) and Osaic Holdings Inc. (0.03%). How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLineRx's stock price today? One share of BLRX stock can currently be purchased for approximately $2.07. How much money does BioLineRx make? BioLineRx (NASDAQ:BLRX) has a market capitalization of $127.37 million. The biotechnology company earns $-24,950,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How can I contact BioLineRx? BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101. This page (NASDAQ:BLRX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.